ClinicalTrials.gg
Status unknownNCT01983527CADACUpdated Nov 14, 2013

Corticosteroids and / or Arthrographic Distention in the Treatment of Adhesive Capsulitis

An interventional study of Arthrographic distention and Intra-articular corticosteroid Depo Medrol in Adhesive Capsulitis and Frozen Shoulder, sponsored by Imelda Hospital, Bonheiden. Status unknown at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-11-14.

Sponsored by Imelda Hospital, Bonheiden · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Nov 2013), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Arthrographic distention of the shoulder joint is an increasingly popular treatment option in the management of patients with frozen shoulder. Most have included the intra-articular injection of a corticosteroid as part of the procedure, but it is not known if this is necessary. It is also not known whether arthrographic distention using steroid and saline is better than intra-articular steroid injection alone.

The purpose of this study is to determine whether there is an additional benefit in the combination of arthrographic distention plus intra-articular corticosteroid injection compared to arthrographic distention or intra-articular corticosteroid injection alone.

02

Conditions studied

  • Adhesive Capsulitis
  • Frozen Shoulder

Browse trials for

Keywords

  • Arthrographic distention
  • Hydrodilatation
  • Intra-articular corticosteroid injection
03

In context

Bursitis

384 studies on the registry are indexed under Bursitis; 111 are open to participants now.

This study's planned enrollment of 132 is above the median of 44 across 347 interventional studies indexed under Bursitis.

Browse Bursitis studies →

Lead sponsor

Imelda Hospital, Bonheiden is the lead sponsor of 7 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pain and stiffness in predominantly 1 shoulder for 4 weeks or longer
  • Restriction of passive motion of greater than 30° in 2 or more planes of movement (measured to onset of pain with goniometer)

Exclusion criteria

Exclusion Criteria:

  • Previous arthrographic distention and/or injection
  • Systemic inflammatory joint disease
  • Radiological evidence of osteoarthritis of the shoulder or fracture
  • Signs of a complete rotator cuff tear
  • to arthrogram and/or distention
  • Lack of written
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
132 participants (estimated)

Study arms

  • Experimental
    Arthrographic distention + intra-articular corticosteroid

    Arthrographic distention of the glenohumeral joint with injection of 5 ml contrast, 1 ml (40 mg) Depo Medrol(Methylprednisolone Acetate Injectable Suspension), 15 ml local anaesthetic (Prilocaine) and up to 15 ml saline.

    Procedure: Arthrographic distention · Drug: Intra-articular corticosteroid Depo Medrol

  • Active comparator
    Arthrographic distention

    Arthrographic distention of the glenohumeral joint with injection of 5 ml contrast, 15 ml local anaesthetic (Prilocaine) and up to 15 ml saline.

    Procedure: Arthrographic distention

  • Active comparator
    Intra-articular corticosteroid

    Arthrographic pseudodistention of the glenohumeral joint with injection of 5 ml contrast and 1 ml (40 mg) Depo Medrol(Methylprednisolone Acetate Injectable Suspension).

    Drug: Intra-articular corticosteroid Depo Medrol

Interventions

  • ProcedureArthrographic distention

    Arthrographic distention of the glenohumeral joint with injection of 5 ml contrast, 15 ml local anaesthetic (Prilocaine) and up to 15 ml saline.

    Also known as: Hydrodilatation

  • DrugIntra-articular corticosteroid Depo Medrol

    Intra-articular injection of 1 ml (40 mg) Depo Medrol(Methylprednisolone Acetate Injectable Suspension)

06

What researchers measure

Primary outcomes

  1. Shoulder pain and disability index(SPADI)

    Time frame: 4 weeks

Secondary outcomes

  1. Shoulder pain and disability index (SPADI)

    Time frame: weekly for a period of 3 months plus at follow-up (4 months and 12 months)

  2. Overall pain score

    Universal pain scale

    Time frame: weekly for a period of 3 months, plus at follow-up (4 months and 12 months)

  3. Range of motion

    * Total shoulder abduction (in degrees, measured with goniometer) * External rotation in neutral position (in degrees, measured with goniometer) * Hand behind back (highest reachable anatomical landmark)

    Time frame: 4 weeks, 4 months and 12 months

07

Study locations

1 site
  • Imelda Hospital
    Bonheiden, Antwerpen 2820, Belgium
    • Rolf Symons, MD · Contactrolf.symons@imelda.be · +32(0)15/50.62.31
    • Symons Rolf, MD · Principal investigator
    • Demeyere Annick, MD · Principal investigator
    • Vankan Yoeri, MD · Principal investigator
    • Perdieus Dirk, MD · Principal investigator
    • Van Raebroeckx Antoon, MD · Principal investigator
    • Ruette Peter, MD · Principal investigator
08

References and documents

Publications

  • Jacobs LG, Barton MA, Wallace WA, Ferrousis J, Dunn NA, Bossingham DH. Intra-articular distension and steroids in the management of capsulitis of the shoulder. BMJ. 1991 Jun 22;302(6791):1498-501. doi: 10.1136/bmj.302.6791.1498. PubMed 1855018 ↗
  • Corbeil V, Dussault RG, Leduc BE, Fleury J. [Adhesive capsulitis of the shoulder: a comparative study of arthrography with intra-articular corticotherapy and with or without capsular distension]. Can Assoc Radiol J. 1992 Apr;43(2):127-30. French. PubMed 1562888 ↗
  • Gam AN, Schydlowsky P, Rossel I, Remvig L, Jensen EM. Treatment of "frozen shoulder" with distension and glucorticoid compared with glucorticoid alone. A randomised controlled trial. Scand J Rheumatol. 1998;27(6):425-30. doi: 10.1080/030097498442244. PubMed 9855212 ↗
  • Buchbinder R, Green S, Forbes A, Hall S, Lawler G. Arthrographic joint distension with saline and steroid improves function and reduces pain in patients with painful stiff shoulder: results of a randomised, double blind, placebo controlled trial. Ann Rheum Dis. 2004 Mar;63(3):302-9. doi: 10.1136/ard.2002.004655. PubMed 14962967 ↗
  • Khan AA, Mowla A, Shakoor MA, Rahman MR. Arthrographic distension of the shoulder joint in the management of frozen shoulder. Mymensingh Med J. 2005 Jan;14(1):67-70. PubMed 15695959 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2013, a primary completion of Dec 2014 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2013
First posted
Nov 14, 2013
Start
Dec 2013
Primary completionEst.
Dec 2014
CompletionEst.
Nov 2015
Last update
Nov 14, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01983527
Lead sponsor
Imelda Hospital, Bonheiden
Responsible party
Symons Rolf (Symons Rolf, MD, Imelda Hospital, Bonheiden) — Principal investigator
First posted
Nov 14, 2013
Start date
Dec 2013
Primary completion
Dec 2014 (estimated)
Completion
Nov 2015 (estimated)
Last update
Nov 14, 2013

Study contacts

Rolf Symons, MD
Contact
rolf.symons@imelda.be
+32(0)15/50.62.31
Rolf Symons, MD
principal investigator · Imeldaziekenhuis

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion